BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8845475)

  • 21. [Efficacy and safety of two methods of administration of granisetron injection for nausea and vomiting induced by chemotherapy for tumors in hematopoietic organs--a randomized crossover comparison between intravenous drip infusion and intravenous bolus injection].
    Tsudo M; Moriguchi T
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1747-53. PubMed ID: 9757201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.
    Yarker YE; McTavish D
    Drugs; 1994 Nov; 48(5):761-93. PubMed ID: 7530631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    Ritter HL; Gralla RJ; Hall SW; Wada JK; Friedman C; Hand L; Fitts D
    Cancer Invest; 1998; 16(2):87-93. PubMed ID: 9512674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
    Carmichael J; Harris AL
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):123-8. PubMed ID: 14634790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy.
    Keating GM; Duggan ST; Curran MP
    CNS Drugs; 2012 Sep; 26(9):787-90. PubMed ID: 22834568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy.
    Friedman CJ; Burris HA; Yocom K; Blackburn LM; Gruben D
    Oncologist; 2000; 5(2):136-43. PubMed ID: 10794804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
    Kim JE; Hong YS; Lee JL; Kim KP; Park SJ; Sym SJ; Shin DB; Lee J; Park YS; Ahn JS; Kim TW
    Support Care Cancer; 2015 Jun; 23(6):1769-77. PubMed ID: 25465680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
    Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
    Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer R; Fitts D
    J Clin Oncol; 1994 Oct; 12(10):2204-10. PubMed ID: 7931490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
    Mabro M; Granisétron PK
    Bull Cancer; 1999 Mar; 86(3):295-301. PubMed ID: 10210764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
    Kalaycio M; Mendez Z; Pohlman B; Overmoyer B; Boparai N; Jones E; Bolwell B
    J Cancer Res Clin Oncol; 1998; 124(5):265-9. PubMed ID: 9645457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.
    Yang LQ; Sun XC; Qin SK; Chen YX; Zhang HL; Cheng Y; Chen ZD; Shi JH; Wu Q; Bai YX; Han BH; Liu W; Ouyang XN; Liu JW; Zhang ZH; Li YQ; Xu JM; Yu SY
    Chin Clin Oncol; 2016 Dec; 5(6):79. PubMed ID: 28061543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy.
    Uchida M; Ikesue H; Kato K; Ichinose K; Hiraiwa H; Sakurai A; Takenaka K; Iwasaki H; Miyamoto T; Teshima T; Egashira N; Akashi K; Oishi R
    Am J Health Syst Pharm; 2013 Feb; 70(4):343-9. PubMed ID: 23370141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron.
    Coluzzi F; Mattia C
    Future Oncol; 2016 Aug; 12(16):1865-76. PubMed ID: 27184113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial.
    Tsuji D; Kim YI; Taku K; Nakagaki S; Ikematsu Y; Tsubota H; Maeda M; Hashimoto N; Kimura M; Daimon T
    Support Care Cancer; 2012 May; 20(5):1057-64. PubMed ID: 21590327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
    Tan EH; Ang PT; Khoo KS
    Support Care Cancer; 1994 May; 2(3):197-200. PubMed ID: 8032707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
    Gralla RJ; Navari RM; Hesketh PJ; Popovic W; Strupp J; Noy J; Einhorn L; Ettinger D; Bushnell W; Friedman C
    J Clin Oncol; 1998 Apr; 16(4):1568-73. PubMed ID: 9552067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.
    Dempsey CL; Coop AJ; Shillington A; Farley PA; Eberhardt DR; O'Briant S
    Am J Health Syst Pharm; 2004 Apr; 61(8):781-6. PubMed ID: 15127961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.
    Italian Group for Antiemetic Research
    N Engl J Med; 1995 Jan; 332(1):1-5. PubMed ID: 7990859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.